Mastitis in Small Ruminants by Mwenge Kahinda, Christine T.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
136,000 170M
TOP 1%154
5,500
1
Chapter
Mastitis in Small Ruminants
Christine T. Mwenge Kahinda
Abstract
Bacterial mastitis in small ruminants is a complex disease, with massive  
economic loss in dairy sheep/goat industry due to poor productivity. The current 
mastitis prevention strategy relies on culling of infected ewes or does and or the 
use of antimicrobial agents to eliminate the bacterial infection. This has a potential 
risk for developing antibiotic resistant bacteria, posing human health risk from 
consumption of raw sheep or goat dairy products. Existing experimental and 
licensed vaccines on the market are ineffective against reducing the risk of mastitis 
in herds or flocks. Raising the needs for development of improved vaccines against 
mastitis for use in sheep and goats. This review examines, current understanding of 
the pathological processes and immunological responses against bacterial mastitis, 
using S. aureus as an example. By highlighting the protective defense mechanism 
induced in the udder against S. aureus mastitis. Based on evidence from published 
studies on pathological process and protective immune response mechanism, the 
need for improved vaccines for prevention of mastitis in small ruminant is high-
lighted and the development of a vaccine capable of enhancing immune response 
mechanism, that reduce the establishment of intramammary infection through 
induction of local IgA, IgG2 and Th17 immune responses is proposed.
Keywords: Mastitis, S. aureus, Pathogenesis, pathophysiology, vaccination
1. Introduction
Mastitis is a complex disease that results in inflammation of the mammary 
glands due to infection or mechanical injury. Host, pathogen, and environmental 
predisposing factors play major role in the development of mastitis. Most cases of 
mastitis of small ruminant occur as a result of bacterial intramammary infection 
(IMI), which are generally a contagious infection resulting from mammary and 
cutaneous carriages of bacterial agents and or spreading of bacteria during the 
milking process. The inflammatory response induced by the host is aimed at remov-
ing the irritant and repairing damaged mammary gland tissues to ensure normal 
functioning of the udder. Inability of the host to control IMI leads to persistent 
inflammatory response (chronic mastitis) that leads to premature culling of the 
affected ewes [1], loss of udder function, reduced milk yield [2], and quality [3, 4] 
and occasionally death. In addition, reduced milk production also affects livestock 
productivity, as it results in lower growth rates of suckling lambs [1]. As such, mas-
titis of small ruminant has a significant economic impact in the livestock industry.
Mastitis in small ruminants caused by bacterial intramammary infections presents 
in two forms i.e., subclinical mastitis or clinical mastitis as depicted in Table 1, with 
varying severity from acute infections that last for short period of time to chronic 
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Ruminant Inflammatory Changes
Milk Clinical  
Manifestation  
Udder
Sheep No visible abnormality; high 
bacterial count; reduced milk 
production; SCC > 500 x10^3 
cells/mL; changes in milk 
composition
Subclinical No visible signs of 
inflammation;
Visible changes in milk e.g., may 
be blood tinged or yellow,may be 
thick, “lumpy”, or very watery
Clinical Visible abnomalities in the 
udder; udder may be firm, 
swollen etc. the gravity of 
the abnomality varies based 
on disease severity.
May contains clots, flakes, or 
discolored secretion
Subacute (mildly 
clinical)
Swollen, red udders, hot 
and painful to the touch; 
hard sensitive udder;
Reduced milk secretion, contains 
clots, flakes, or discolored 
secretion; appears watery
Acute (sudden onset of 
inflammation, can be 
fatal)
Swollen; hot; red and 
painful to touch
Abnormal milk appearance; 
bloody fluid
Peracute (Severe 
inflammation, fatal or 
loss of affected udder)
Visibly abnormalities; 
swollen; cold; blue/black; 
may slough off; gangrenous
May have no milk production; 
reduced yield and composition; 
contains purulent material 
(pus);
Chronic Hard or lumpy; abscesses; 
may have scars; may be 
fibrotic; swollen teat; may 
contain a hard core of pus; 
asymmetrical appearance; 
enlarge or shrunken;
Goat No visible abnormality; But 
laboratory test present with: 
high bacterial count; reduced 
milk production; reduced 
antioxidant content; changes in 
milk composition
Subclinical No visible signs of 
inflammation;
Visible abnormalities in 
the milk (varies based on 
severity); increase in whey 
proteins; increase in albumin 
concentration; a reduced lactose 
concentration and milk fat; 
increase electrical conductivity
Clinical mastitis Visible abnormalities in 
the udder (varies based on 
severity)
Contains clots, flakes, or 
discolored secretion;
Subacute (mildly 
clinical)
slightly swollen and tender
Reduced milk secretion, contains 
clots, flakes, or discolored 
secretion; appears watery
Acute (sudden onset of 
inflammation, can be 
fatal)
Swollen, red udders, hot 
and painful to the touch
Serum-like milk secretion. Milk 
may appear reddish and may 
contain gas
Peracute (Severe 
inflammation, fatal or 
loss of affected udder)
Swollen, discolored (reddish 
to purple/black), cold to 
touch; may be gangrenous
Milk may contain flakes, 
purulent material (pus) and be 
discolored; Reduced yield and 
composition
Chronic (persistent 
infection, may 
be incurable and 
recurring)
Hard, fibrotic, abscesses 
shrunken or lumpy
Table 1. 
The different forms of mastitis in small ruminant and plausible signs in relation to the severity of infection.
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infection which are persistent and long term. Herein, we discuss mastitis in small 
ruminant, focusing on sheep and goat.
1.1 Sheep
The most common form of mastitis in sheep is subclinical mastitis, with a 
reported prevalence of 5–30% [5] and sometimes up to 50% [6]. Subclinical mas-
titis is difficult to identify, mainly due to lack of clinical signs. Subclinical mastitis 
can only be detected by milk bacteriological test or somatic cells count (SCC) (i.e., 
inflammatory cells and some epithelial cells) [7–10]. In sheep a SCC of >500 x 103 
cells/mL of milk [7, 8] and or a positive California Mastitis Test (CMT) [9, 10] is 
considered subclinical mastitis. In most cases, ewes with subclinical mastitis appear 
healthy, but have decrease milk production [11, 12] and changes in the composi-
tion of milk due to the inflammation. Subclinical mastitis may affect lambs of 
infected ewes by causing them to have a poor growth rate, lower weaning weight 
and occasional death [11, 13]. As such, subclinical mastitis has significant financial 
implications for both dairy sheep flocks due to its impact on milk production and 
quality [11, 12] in meat-producing sheep flocks as it affects lambs growth rate and 
weaning weight [11, 13].
Subclinical mastitis due to bacterial IMI may progress to acute or chronic 
mastitis. Progression of subclinical mastitis to clinical mastitis can occur as 
a result of the following events. 1) Subclinical mastitis-causing bacteria can 
be transmitted from an infected under to an uninfected udder during milking 
as a result of poor hygiene practices by milkers whereby they can transmit 
the infecting bacteria from their hands or from using contaminated shared 
milking equipment and udder washcloths. These practices provide the bac-
teria access to the teat canal, where successful bacterial growth subsequently 
results in mastitis. 2) Nutritional deficiency adversely affects the animal host 
defense mechanism, and may promote disease progression to clinical masti-
tis. Katsafadou et al. [14], associated nutritional deficiencies with impaired 
leucocyte function or mammary defense. Here nutritional elements such as 
Selenium, Zinc, vitamin E and Vitamin A deficiencies have been linked to an 
increased risk of mastitis in ewes [14–16]. For example, Selenium and Vitamin 
E are important in maintaining neutrophil function [17], they are known to 
protect leucocytes against reactive oxygen species (ROS)-induced damage 
[14–16]. Zinc forms part of teat keratin and skin, it has been suggested that 
deficiency in Zinc and vitamin A negatively affects the integrity of the teat 
and epithelia [14–16]. This could allow the colonization of the teat by infecting 
bacteria, coupled with other deficiencies that result in the establishment of 
clinical mastitis.
Clinical mastitis usually occurs in less than 5% of mastitis cases in sheep  
[5, 10, 18]. However, clinical mastitis in sheep is often observed as sporadic cases 
or during occasional herd outbreaks [5, 10]. Clinical mastitis can transition from 
subacute to chronic with increasing disease severity. Clinical mastitis is easy to 
identify, it presents with clearly observable clinical signs and physical changes in 
the udder, such as blue discoloration of the udder. Udders with clinical mastitis are 
usually swollen and sometimes painful to the touch. sheep affected with clinical 
mastitis go off feed, are lethargic, and often refuse to allow their lambs to nurse, 
resulting in lower growth rates of suckling lambs. The appearance and composition 
of milk obtained from ewes affected by clinical mastitis is abnormal, it may be dis-
colored, watery, may contain blood or serum, may be foul-smelling if it contains 
pus and has visible clots or flakes.
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1.2 Goats
The prevalence of subclinical mastitis in goat is 5–45% [5, 19]; some authors 
suggest it’s 15–40 times more prevalent than clinical mastitis [20]. As in other 
ruminants, subclinical mastitis in goat is difficult to identify by clinical signs. 
Subclinical mastitis in goat presents with high bacterial count in milk; reduced milk 
production and quality, as well as a high SCC. However, SCC are not reliable indica-
tors of subclinical mastitis diagnosis in goat [21, 22]. Generally, healthy goats have a 
higher milk SCC compared to sheep, and other ruminants such as cows. In addition, 
the number of SCC in goat milk various based on stage of lactation, SCC has been 
reported to reach 3.6 x10^6 cells/ mL at end of lactation [23]. Some have reported a 
SCC ≥ 10^6 cells/mL as an indication of subclinical mastitis in goat; however, this 
set minimum is usually combined with a bacteriological test to confirm diagnosis. 
SCC alone is not used to diagnose subclinical mastitis in goats, as shown by Hussein 
et al. [21], SCC ≥ 10^6 cells/mL threshold was unable to differentiate subclinical 
mastitic goat from healthy goats, thus confirming the use of bacteriological test as 
the most reliable indicator of subclinical mastitis in goats [21].
In goat subclinical mastitis usually precedes clinical mastitis, as its act as a source 
of infection for healthy animals [19]. Clinical mastitis presents with visible abnor-
malities in the udder and or milk that varies based on the severity of the infection, 
as mentioned in Table 1. Clinical mastitis in goats is also classified into four groups 
based on disease severity, i.e. subacute, acute, peracute and chronic. As mentioned 
in Table 1, above, this ranges from a mild infection to severe, presenting with pain, 
heat, swelling, redness, and reduced and abnormal secretion such as clots, flakes, or 
watery milk. May develop fever, depression, weakness, anorexia and may be fatal.
2.  Important bacterial pathogens for vaccine development against 
mastitis in small ruminants
Several bacterial agents are associated with clinical or subclinical mastitis in 
small ruminants [5]. A very exhaustive list of gram-positive and gram-negative 
bacteria has been implicated in mastitis of sheep and goats. However, for the 
purpose of this review, the most implicated organism with potential for commercial 
vaccine development against mastitis of both sheep and goats will be discussed.
2.1 Sheep
Over 30 bacterial species have been isolated from sheep with mastitis [1, 24–26]. 
The most implicated organisms in sheep mastitis are Staphylococcus aureus [24, 27, 28]; 
Mannheimia spp. [29] Streptococcus spp. [30, 31]; and non-aureus staphylococci.
S. aureus is a zoonotic, Gram-positive bacteria that occurs as a mammalian commen-
sal and opportunistic pathogen. S. aureus is the most common cause of mastitis in sheep 
and the major mastitis-causing agent isolated in 70% of clinical mastitis cases in dairy 
flocks [10, 24]. It is responsible for about 40% of mastitis cases in ewes suckling lambs 
and 80% mastitis cases in milking ewes [24, 27, 32]. Cases of mastitis due to S. aureus 
ranges from subclinical mastitis to severe gangrenous mastitis. It is important to note 
that S. aureus subclinical mastitis infections are extremely difficult to treat, cure and are 
highly contagious. As such, animals with S. aureus mastitis are culled or milked last to 
prevent spread of infection to other members of the herd or flock.
Other non-aureus staphylococci, are associated with subclinical intramammary 
infections [33], of these, Staphylococcus epidermidis is the most common species 
associated with ovine mastitis [34].
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M. haemolytica is an aerobic, non-motile, bipolar, gram-negative rods, non-
spore-forming opportunistic bacterium carried in the nasal and nasopharyngeal 
cavities of healthy animals. M. haemolytica is the most common cause of mastitis 
in meat and wool sheep producing systems [1, 29, 32]. M. haemolytica causes 
severe clinical mastitis, where the infected mammary glands are greatly enlarged, 
tense, blue-black, with watery secretion containing flakes and widespread gan-
grenous necrosis of the udder [29]. In some flocks M. haemolytica mastitis is more 
significant than S. aureus induced mastitis, due to its transmission by suckling 
lambs [29]. As a result, pneumonia may be observed in suckling lambs of ewes 
with M. haemolytica mastitis. Based on a 2008 research study by Arsenault et al., 
[1], the prevalence of M. haemolytica clinical mastitis is similar to S. aureus masti-
tis in meat-producing flocks, thus making it a significant organism in the etiology 
of mastitis in sheep.
Streptococcus spp. are zoonotic, anaerobic, non-spore-forming, Gram-positive, 
catalase-negative, homofermentative, spherical or ovoid cocci that occur as single 
or in pairs or chains [23]. They are usually responsible for sporadic outbreaks of 
mastitis in sheep and goats [30, 31, 35, 36]. Mastitis due to Streptococcus spp. occurs 
at a rate of 23–31% in flocks [25, 37]. Mastitis caused by Streptococcus spp. are more 
frequent in machine-milked flocks [25, 38, 39] or as a result of poor hygiene during 
milking [40], suggesting that proper milking practices may reduce the incidence 
of mastitis due to streptococci. S. agalactiae, S. uberis, S. dysagalactiae and S. equi 
subsp.zooepidemicus are the most isolated Streptococcus spp. causing mastitis in dairy 
ruminants [41].
2.2 Goats
Several bacterial species have been isolated from goats with mastitis, for 
example. Staphylococcus spp.; Streptococcus spp.; Bacillus spp.; Listeria spp.; 
Corynebacterium spp.; Pseudomonas spp.; Mycoplasma spp.; Mannheimia haemo-
lytica; Clostridium perfringens and Escherichia coli [5, 10, 22, 25, 41–45]. However, 
non-aureus staphylococci are the most prevalent causative agent of subclinical mas-
titis in goats [10, 22, 42, 46–48] and Staphylococcus aureus is considered to cause the 
highest pathogenicity in goat mastitis, along with minor prevalence of Escherichia 
coli, Streptococcus agalactiae, Mannheimia haemolytica [10, 22, 42, 45–49]. S. aureus-
induced mastitis in goat ranges from subclinical to gangrenous mastitis, which is the 
most severe form of the disease [45, 47]. As with sheep mastitis, S. aureus mastitis 
are difficult to treat, infected goats act as reservoir and source of spread.
Non-aureus staphylococci are the most prevalent bacteria from goats with 
subclinical mastitis, with up to 100% incidence [10, 48, 50–52]. The most isolated 
bacteria from these species are Staphylococcus chromogenes, Staphylococcus epidermidis, 
Staphylococcus simulans, Staphylococcus xylosus, and Staphylococcus caprae [10, 52–54]. 
S. chromogenes and S. epidemidis are associated with higher milk SCC [53] compared 
to other non-aureus staphylococci, however, the increase in SCC is lower than in S. 
aureus mastitis [10]. S. caprae and S. simulans have been linked to persistent mastitis 
in goat [55]. These bacteria do not produce coagulase, an enzyme responsible for 
prothrombin activation leading to the coagulation of plasma [56, 57]. They are 
opportunistic bacteria with the ability to produce biofilms [58], which enables these 
bacteria to persist on milking equipment, serving as a source of spread to other ani-
mals in cases of poor hygiene and milking practices. Non-aureus staphylococci have 
been reported to carry a wide range of antimicrobial resistance genes, which allows 
for persistent infections [59].
For vaccine development against mastitis in sheep and goat, it is imperative that 
intension and efforts are made towards the development of a vaccine containing 
Mastitis
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bacteria that have the highest pathogenicity or prevalence and has potential to 
impact human safety due to their zoonotic nature such as; S. aureus.
3.  Pathogenesis of bacterial intramammary infection in small ruminant, 
using S. aureus as an example
The pathogenesis of bacterial intramammary infections in small ruminants is 
very complex. It is dependent on the infecting bacteria, bacterial virulence factors, 
and the interaction of these virulence factors with the host immunological response 
in the udder. Of the various bacteria known to cause mastitis in sheep and goats, S. 
aureus is used in this paper as an example to describe the pathogenesis of intramam-
mary infection in sheep and goats, with emphasis on pathological processes that are 
essential for vaccine development.
The pathogenesis of S. aureus mastitis is very complex. It is associated with 
various surface proteins and virulence factors that are differentially expressed at 
various phases of the infection. This process entails three key steps, that is adhe-
sion, invasion and evasion. In brief, the first step in the pathogenesis process is 
adhesion to epithelial cells and extracellular matrix, which permits the bacteria to 
avoid being flushed out of the udder from milk flux pressure [60]. During this step 
S. aureus expresses several virulent factors involved in adhesion, such as Microbial 
Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMM), 
e.g. protein A, elastin-binding proteins, collagen-binding protein etc.; surface-
associated capsule (which inhibits phagocytosis and promotes adhesion); pepti-
doglycan (which activates complement); teichoic acids (involved in adhesion and 
colonization, cell division and biofilm formation) [60–64]. Here, the formation 
of biofilm protects S. aureus from host immune response or antibiotics [65, 66]. In 
the second step of this process, S. aureus again expresses different virulence fac-
tors to establish infection by invasion into host cells and tissues. This step or phase 
entails penetration and destruction of mammary glands tissues by the bacteria and 
involves the expression of the following virulence factors: haemolysins (i.e., alpha, 
beta, gamma & delta, these lyse cells); leukocidin (damages polymorphonuclear 
leucocytes); panton-valentine leukocidin (a β-pore-forming toxins); enterotoxins 
(heat stable toxin); epidermolytic toxin (this is a serine protease that causes split-
ting of desmosomes or intercellular bridges in the stratum granulosum); toxic 
shock syndrome toxin (TSST-1, causes leakage of endothelial cells and penetration 
of mucosal barrier) [60–64]. Together, these virulence factors result in damage to 
the epithelium of the cistern, duct and alveoli and perpetuate the infection, even-
tually leading to the clinical signs observed during mastitis. Subsequent to these 
events or perhaps in unison, the final step in the pathogenetic process is an evasion 
of the host immune response. Here, S. aureus escapes the host immune response 
by producing the various virulence factors that helps it not only to evade but also 
modulate the host immune response in its favor. For example: enzymes such as 
coagulase (that activates a coagulase reacting factor (CRF), which is believed to 
coat bacteria with fibrin to prevent opsonisation and phagocytosis); staphylokinase 
(fibrinolysin); Hyaluronidase (hyaluronic acid, which facilitates the spread of S. 
aureus through tissues); deoxyribonuclease; lipase; phospholipases; proteases; 
and again other already expressed virulence factors that were released during the 
adhesion and invasion process, these are continuously differentially expressed as 
required to anchor the infection and avoid elimination of S. aureus by mammary 
gland immune responses. S. aureus virulence factors target the main cells involved 
in mammary immunity, such as neutrophils and macrophages by counteracting 
their actions [60].
7
Mastitis in Small Ruminants
DOI: http://dx.doi.org/10.5772/intechopen.97585
3.1 Immune response and pathological process in the mammary gland
3.1.1 Teat and teat cistern
The teat canal is the first physical barrier that bacterial agents meet before they 
can spread into the mammary glands [67–70]; protection against bacterial agents 
is provided by bacteriostatic fatty acids that are present in the keratin plug in the 
teat canal [68–70]. As such, invading microbial organisms are trapped in the lining 
of the teat canal by these hydrophobic lipids. The trapped microbial organisms are 
flushed out together with teat canal epithelial cells during the first outflow of milk. 
In addition, ewes teat are known to close 20 to 30 minutes; however, total closure 
occurs two hours post milking [69], as part of the first line of defense against invad-
ing microbial organisms. For this reason, it is recommended to move ruminants to 
clean areas after milking and provide feed to avoid laying down and exposure to 
contaminating environmental microbial organisms until teats end close [69]. If bac-
teria gain access to the teat canal, the bacterial adherence property is used to estab-
lish infection. As mention previously, using S. aureus as an example, MSCRAMM 
and capsular proteins are differentially expressed to permits attachments of the 
bacteria to the epithelial tissues. This mechanism is not only employed by S. aureus 
but other mastitis causing bacteria such as, M. haemolytica [71], Streptococcus spp. 
[72]. Therefore, adherence of microbial agent to teat epithelial tissue permits them 
to invade or penetrate this protective barrier and migrate to the teat duct.
3.1.2 The teat duct
Once the bacteria reach the teat duct, a cascade of complex sequence of events 
determines the outcome of the immune response induced. Here, somatic cells/
leukocytes present in milk and component of the innate immune response in 
the teat duct act as a defense against any invading bacteria that has managed 
to by-passed the physical barrier in the teat cistern. The milk leukocytes act as 
phagocyte and secrete an array of immune-related components in milk, such as 
cytokines (e.g. TNF-α, IFN-γ, GM-CSF, IL-8, and IL-12), chemokines, reactive 
oxygen species (ROS), and antimicrobial peptides (Lactoferrin, defensins, and 
cathelicidins) [73]. In addition, inducible lymphoid nodules (containing B and 
T lymphocytes, as well as immune cells that express major histocompatibility 
complex (MHC) class II) that are present in the teat duct act in synergy with 
viable milk leucocytes to get rid of the invading bacteria. Based on this, an array 
of multiple cells are involved in the immune response of the teat duct against 
invading bacteria, these includes neutrophils, macrophages, αβ T cells, γδ T cells, 
B cells and inducible lymphoid cells etc. [69, 73].
A plausible scenario for the sequence of events that occurs when a bacteria is 
invading through the teat duct could be summarized as follows. As the bacteria 
invade the teat duct to colonize and establish infection, it releases a mirage of viru-
lent factors, amongst these pathogen-associated molecular patterns (PAMPS) such 
as peptidoglycan and lipoteichoic acids in the case of S. aureus. These are recognized 
by Toll-like receptor (TLR)-2 on the surface of epithelial cells lining the teat ducts  
[70, 74, 75]. TRL2 stimulation leads to the release of IL-8; CCL2 and CCL4 [69, 74, 
76]. IL-8 is a potent chemo-attractant and activating factor for neutrophils. CCL2 
and CCL4 are chemoattractant for monocytes and macrophages [69, 76]. S. aureus 
PAMPs can also be recognized through formylated peptide receptors, mannose-
binding lectins (MBL), ficolins, and complement molecules [70], resulting in the 
activation of the complement system leading to ingestion and killing of S. aureus. 
In addition, B cells in milk and milk macrophages process antigens from invading 
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bacteria and present these antigens in association with MHC class I or II on their 
membranes to different T cells.
As part of the innate response, activated neutrophils and tissue macrophages 
migrate into mammary glands to eliminate the invading bacteria and initiate the 
inflammatory response. The outcome of these early events results in increased 
neutrophils in the milk and an elevation in SCC, seen in subclinical mastitis, under 
normal state the udder tissue and milk mainly contain macrophages and during 
infection neutrophils are dominant in the udder tissue and milk [70].
Neutrophils/PMNs (Polymorphonuclear neutrophils) are the first recruited 
cells at the site of infection and are known to form part of the earliest protective 
response against bacterial mastitis in ruminants [77]. Their primary function is 
to engulf, phagocytose, and destroy invading bacteria. This is done through two 
pathways, the oxygen-dependent (respiratory burst, which includes the production 
of hydroxyl and oxygen radicals) pathway and or the oxygen-independent (which 
uses peroxidases, hydrolytic enzymes) pathway. Neutrophils also modulate vascular 
permeability and release a variety of inflammatory mediators that coordinate both 
the innate and adaptive immune response [69, 74]. In addition, neutrophils contain 
bactericidal peptides such as defensins; myeloperoxidase; S100-A9 protein, elastase; 
cathepsin types B, D, and G; procathepsins within their intracellular granules, these 
peptides can kill a variety of mastitis pathogens [69, 78–80]. However, neutrophil 
release oxidants and proteases are non-specific, as such they may also contribute to 
host mammary epithelium damage, and e.g., hydroxyl radicals may damage mam-
mary epithelium [81]. Neutrophils undergo apoptosis or programmed cell death 
after completing their task and are removed by macrophages [81].
Milk macrophages and recruited macrophages (blood monocytes that differenti-
ate in mammary tissue) act as antigen-presenting cells (APCs), by processing and 
presenting antigens to CD4+ T cells in association with MHC class II [82]. These 
macrophages ingest and phagocytose the invading bacteria, destroying them with 
proteases and ROS. However, as with neutrophils, macrophages also contribute to 
mammary gland epithelial damage due to their non-specific killing with proteases 
[83]. Macrophages have been shown to be inefficient in killing some mastitis patho-
gen by promoting their multiplication intracellularly [83].
In healthy udders, the predominating lymphocytes are αβ T cells, with a CD3+ 
CD8+ phenotype, that act as cytotoxic or suppressor T cells [84]. γδ T cells medi-
ate cytotoxicity in a none restricted manner, with variable involvement of MHC 
molecules and also play a role in antibacterial immunity through production of 
granulysin [73, 85] expression of CD95L and TNF-related apoptosis-inducing 
ligand, that engage with several death receptors on target cells [85]. In addition, 
activated γδ T cells stimulate other immune cells e.g., dendritic cell maturation, 
through the production of TNF-α [85], IFN-γ, and IL-17 [86]. In mastitis, these 
cells form part of the early response as is reported in a mouse experimental mastitis 
study, where infection with S. aureus, induced an early influx of γδ T cells produc-
ing IL-17 into the mammary glands [87]. IL-17 activates mammary epithelial cells 
and enhances neutrophil infiltration through an expression of CXCL1, CXCL2, and 
CXCL5 chemokines. This enhances host clearance of the invading bacteria [87, 88]. 
It has also been suggested that γδ T cells plays a role in repairing damaged mammary 
gland tissues during and after mastitis. [89].
Whereas, αβ T cells recognize an antigen through membrane receptors, as such 
their specificity, diversity, and memory features are defined by the type of receptor 
they used to recognize antigens [73].
The efficiency of phagocytic killing culminating from events mentioned above 
determines the severity of the disease being established, i.e., the disease progression 
from subclinical mastitis to gangrenous mastitis.
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Mastitis causing bacteria may by-pass the natural defense and innate immu-
nity in the teat canal and establish infection in the intramammary area. Indeed, 
mastitis-causing organism, such as S. aureus secretes an array of virulence 
factors to facilitate invasion and deeper penetration into the mammary glands. 
S. aureus secretes cytolytic toxins such as α, β, γ, δ-haemolysins [90], phenol 
soluble modulins (PSMs) and bi-component leukocidins. These exert their 
role through pore-forming on host immune cell membrane, causing osmotic 
leakages of cell content, leading to lysis of neutrophils, monocytes, platelet, 
and erythrocytes. S. aureus also engages a wide range of virulence factors to 
restrain neutrophil activation, chemotaxis and phagocytosis and also target 
key host effector proteins that are released by host immune cells. For example, 
extracellular fibrinogen-binding (Efb) protein, coagulase (Coa), extracellular 
matrix-binding protein (Emp), extracellular adhesive protein (Eap), chemotaxis 
inhibitory protein (CHIPS) and staphylococcal complement inhibitor (SCIN) 
proteins. For example; Efb plays an immunosuppressive role by interfering 
with the complement system, it has been reported to significantly exacerbate 
S. aureus infections, impairs wound healing, and inhibit platelet aggregation 
and thrombus formation [91]. Through this mechanism, Efb facilitate S. aureus 
survival and persistent infection. CHIPS, is a potent inhibitor of neutrophil and 
monocyte chemotaxis towards C5a and formylated peptides [92]. Furthermore, 
macrophages also synthesize complements, such as component 3 (C3) in the 
mammary gland. These complements are involved in evoking and controlling 
the inflammatory process, bacterial opsonization and presentation, leukocytes 
recruitment and killing of microbial agents in the mammary glands [93, 94].
In a nutshell, S. aureus virulence factors promote the establishment of mastitis 
in the udder, through secretion of an array of virulence factors that facilitates 
adherence to mammary epithelium, invasion of mammary glands, and evasion 
of mounted host immune response mechanism against it by modulating counter-
responses, e.g. S. aureus expresses T-cell superantigens such as, TSST-1, staphy-
lococcal enterotoxin A, staphylococcal enterotoxin B, etc.) that bind to a specific 
subset of the variable Vβ chains of the T-cell receptor (TCR), leading to polyclonal 
proliferative responses and clonal deletion of T lymphocytes [95].
3.1.3 Alveoli
Mechanisms of the innate immune response previously described remain the 
same, but failure to resolve the induced inflammatory response lead to engagement 
of the adaptive immune response to eliminate the bacteria. S. aureus protective 
immune response mechanism entails both arms of the adaptive immune response, 
i.e. cell-mediated and humoral mediated arms of the immune response play a role 
in the clearance of bacterial mastitis. Numerous studies have shown the role of 
both T helper cells, cytotoxic T cells and B cell responses in clearance and resolving 
of bacterial infections. However, these cells have also been implicated in disease 
pathogenesis.
Using our previous scenario, once the bacteria reach the alveoli, the mammary 
epithelial cells lining acts as defense mechanism against the invading bacteria 
triggering a cascade of immunological responses directed against the invading 
bacteria’s virulence factors. In addition, the magnitude of the induced immunologi-
cal response determines the outcome of the inflammatory response (mastitis), i.e., 
the early expression of various inflammatory reaction modulators play a role in the 
severity of the subsequent inflammatory response e.g., IL-1, IL-8, IFN-γ, TNF-α, 
and G-CSF enhanced the activation of neutrophils, whereas IL-12, M-CSF, and 
GM-CSF stimulate enhanced activation of macrophages; IL-2 and IL-6 Stimulates 
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B cells differentiation, and so forth [96] and the type of effector T cell response 
induced is also related to the cytokines in its surrounding.
As the bacteria continue to proliferate in the alveoli, the mammary epithelial 
cells lining the alveoli have various role in protection against invading microbial 
organisms. For instance: 1) the mammary epithelial cells sense and recognizes 
microbial agents through pattern recognition receptors (PRRs), e.g., these cells 
are known to express TLR2 and TLR 4 [97, 98]. These cells recognize invading 
bacteria via the MyD88- dependent TLR (Toll-like receptor) signaling pathway 
[74, 79], 2) the mammary epithelial cells synthesize inflammatory mediators and 
antimicrobial peptides upon recognition of microbial organisms. According to 
various mastitis studies and reports, mammary epithelial cells produce cytokines 
such as, interleukin-8; chemokines such as, CCL5; β-defensins; haptoglobin; cat-
helicidin; lactoferrin; lysozyme, and serum amyloid A [42, 99–101]. The release of 
these inflammatory mediators activate local leukocytes that are normally present 
in the mammary gland tissue, such as macrophages, dendritic cells, and intra-
epithelial lymphocytes, and also immune cells in milk and circulating immune 
cells, such as neutrophils (polymorphonuclear neutrophils (PMN)), and cytotoxic 
natural killer cells.
The adaptive immune response is initiated by activated macrophages; these 
produce cytokines and chemokines, antimicrobial peptides, such as, β-defensins 
and cathelicidins [102, 103]. In addition, macrophages process and present antigens 
through MHC class I or II mechanisms.
Macrophage present antigen through MHC class II to naïve circulating T helper 
cells. Upon activation, these cells subsequently differentiate into antigen-specific 
effector T helper cells based on the type of cytokine in the immediate surrounding, 
e.g., presence of IL-12 surrounding will induce polarization of CD4+ T helper 1 
(Th1) cells, IL-4 will induce polarization of Th2 and a combination of IL-4, TGF-β, 
IL-22 induces Th9 polarization, whereas IL-1β, IL-6, TGF-β & or IL-23 combination 
induces polarization towards Th17 [104, 105] and so forth, thereby inducing specific 
local immune responses. The antigen-specific activated T-cell clonally expands into 
effector cells that produce specific cytokines which activate and induce polariza-
tion of other cells that participate in the immune response. These cells eventually 
differentiate into memory cells. Mastitis results in changes to cytokines concen-
tration in the milk and udder; these changes are reported to differ based on the 
infecting bacteria. In S. aureus mastitis, protective immune responses that leads to 
eventual clearance of the bacteria, is facilitated by an initial increase in the numbers 
of activated Th17, Th1, Th2 cells associated with an increase in pro-inflammatory 
cytokines in the mammary gland, followed by an increase in Treg and anti-
inflammatory cytokines IL-10 [88]. The study conducted in an S. aureus mastitis 
mice model showed that the frequency of these cells changed throughout the course 
of infection [88]. Whereby Th 17 cells producing IL-17 are increased in the early 
phase of a S. aureus mastitis infection, along with an increase in Th1 cells [88]. As 
previously mentioned, IL-17 enhances neutrophil infiltration facilitating bacterial 
clearance. IL-2, TNF-β and IFN-γ produced by Th1 cells promote the activation and 
proliferation of cytotoxic lymphocytes, natural killer cells, and macrophages. As 
the infection progress, the effector T helper cell response shifts to a Th 2 response, 
this is thought to limit the tissue damage due to the inflammatory response, Th2 
secreted cytokines such as, IL-4 which regulate macrophage functions, and inflam-
matory cytokines were increased. IL-4 increase expression of IL-10 [106], which 
inhibits IL-17 expression [88, 107]. As part of the protective immune response 
against mastitis, Zhao et al. [88], reported that Treg cells and IL-10 tightly regulate 
the inflammatory response to mastitis, as observed after the peak of infection in 
mice S. aureus mastitis model.
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Sometimes during infection, extracellular bacteria such as S. aureus avoid being 
targeted by the host response and persist by invading cells and multiplying within 
them, becoming an intracellular infection. In addition, phagocytosed S. aureus is 
able to replicate and multiply in phagocytic cells such as macrophages [108, 109]. 
Here, bacterial antigens are processed and presented on MHC class 1, where they 
are recognized for killing by antigen-specific cytotoxic T cells (CD8+), releasing 
S. aureus for the second round of opsonophagocytosis [110]. Activated antigen-
specific CD8+ cytotoxic T-cells mainly produce IFN-γ and CD8+ suppressor T-cells 
produce regulatory IL-4. The severity of the disease outcome is dependent on the 
efficiency of phagocytic killing that occurs and this as already mentioned, is depen-
dent on the early expression of the various inflammatory mediators [96]. Therefore, 
as the inflammatory response amplifies, with increasing migration of phagocytic 
cells and antigen-specific cytotoxic T cells to the site of infection, S. aureus has 
the ability to form abscess and release a wide variety of virulence factors such as 
haemolysins (alpha, beta, and delta) [60–63], T cells superantigens (enterotoxins, 
TSST-1) [60–63] and several others as mentioned in Section 3 above. These virulent 
factors enable the bacterium to evade detection by the immune system and inhibit 
the host immune response by destroying immune cells.
The humoral response plays an important role in the prevention and control 
of bacterial infections. Three different classes of immunoglobulins, i.e., IgG (sub-
class: IgG1, IgG2, IgG3), IgM, and IgA, play significant roles in mammary gland 
defense against bacterial pathogens. In sheep the predominant immunoglobulin 
G is IgG1, followed by IgG2 then IgG3, however this is dependent of the infecting 
organisms. IgG1 producing plasma cells are associated with a Th2 response whereas 
IgG2 producing cells are associated with a Th1 response. It has been suggested 
that immunoglobulins in colostrum and milk, are transported from blood into the 
mammary secretions as part of normal physiological process during colostrum and 
milk production or through leakage into the mammary gland during inflamma-
tion. For example, during normal physiological process, such as colostrum or milk 
production, blood derived IgG1 specific to intestinal antigens is trafficked into the 
mammary glands, blood derived IgG1 is produced by plasma cells derived from 
stimulated B lymphocytes of the Peyer’s patches [111–114], and has no major role 
in intramammary infection. However, blood derived IgG2 leaks into the mammary 
glands during inflammation and is though to play a significant role in intramam-
mary infection, as it is produced by plasma cells in the skin-associated lymphoid 
tissue and regional lymphoid tissues [111–114]. Blood derived IgG2 has specificity to 
bacterial antigens associated to skin infections [111–114]. In addition, during intra-
mammary infection, antigen-activated plasma cells from regional lymphoid nodes 
present within the mammary glands produce IgA, IgM and IgG2 that are specific for 
antigens present in the mammary gland [111–114]. IgG1, IgG2 and IgM function by 
opsonising, invading bacterial pathogens and make them detectable by neutrophils 
and macrophages for opsonophagocytic destruction [115]. Phagocytosis by PMN is 
regarded as one of the most important defense mechanisms of the mammary gland. 
However, this defense mechanism can be hindered by toxins produced by S. aureus 
such as leukotoxin. IgA acts as a neutralizing antibody to protect the mammary 
gland against bacterial toxins [114]. In addition, IgA prevents the establishment of 
mastitis in the mammary gland through complement fixation, prevention of adhe-
sion of pathogenic microbes to the endothelial lining by binding various adhesion 
receptors, and inhibition of bacterial metabolism by blocking enzymes [113], such 
as Staphyloccocus Enterotoxins. IgA also acts in bacterial agglutination, limiting 
bacterial dissemination and colonization [114, 116]. Immunoglobulin, specifically 
IgA, may play a very import role in protection and prevention of mastitis in small 
ruminants [113, 114].
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4. Approach to new vaccine developments for the prevention of mastitis
Vaccination is a control strategy used to increase the adaptive immunity of 
the animal in order to prevent new infections. The purpose of using vaccines is 
to enhance immunity and reduce the reliance on the use of antimicrobial drugs 
(antibiotics), more so in the case of mastitis in sheep and goats, as the use of 
antibiotics in treatment may result in antimicrobial resistance, e.g., antibiotics 
resistance in Staphylococcus spp., such as methicillin resistant Staphylococcus aureus. 
This poses a human health risk, especially because most mastitis-causing bacteria 
are zoonotic, and some have been reported as cases in humans due to consump-
tion of raw sheep and goat dairy product [117–121]. In addition, there are very few 
veterinary pharmaceutical products licensed for specific use in sheep and goats 
globally. Furthermore, the use of non-steroidal anti-inflammatory agents to allevi-
ate clinical signs of mastitis and improve animal welfare [122], has no impact on 
milk quality. As such, alternatives strategies are needed to prevent mastitis in small 
ruminants. Several experimental vaccines against mastitis, based on formalin-
inactivated whole cells, whole-cell lysate, polyvalent whole-cell Bacterin cultures 
of the vaccine strains or bacteria of interest, produced using old technologies, 
have been shown to play a role in mastitis prevention, by reducing the severity of 
clinical and subclinical mastitis, but does not reduce the incidence of the disease 
[123–126]. Although experimental vaccines against mastitis, based on formalin-
inactivated whole cells, whole-cell lysate, polyvalent whole-cell Bacterin cultures of 
the vaccine strains [123–126], stimulates humoral immune responses, the levels of 
opsonizing antibodies in milk is poor or absent [127]. The lack of efficacy observed 
in conversional experimental vaccines may explain why mastitis vaccines for use 
in sheep and goats have not been developed further. Hence there are currently very 
few commercial vaccines licensed for use in sheep and goats. In addition, current 
vaccines on the market licensed against mastitis are mostly targeted at staphy-
lococcal mastitis in bovine, there aren’t many vaccines against mastitis targeting 
sheep and goats. Of the few vaccines against mastitis on the market, none of them 
are effective against mastitis but label claim indicate some effect. For example, 
Lysigin® (Boehringer Ingelheim) is the only vaccine against staphylococci in the 
US. While, Startvac (Hipra, spain) is the only vaccine licensed in Europe and few 
other coutries including Canada with label claim of some effect against S. aureus, 
E. coli, CNS. However, in controlled experimental studies their effects were none to 
very limited [127–130]. Another vaccine on the market is J5 vaccine from different 
manufacturer (zoetis, Boeringer, etc.) against E. coli mastitis. As with the other 
vaccines mentioned previously, this vaccine is also not very effective but claimed 
for some effect. Lastly, UBAC® (Hipra, Spain) with label claim against S. uberis 
mastitis is yet to be validated under field condition [130]. In comparison, only two 
licensed vaccine, Blue udder (Onderstepport biological products (OBP), South 
Africa), and Vimco ® (Hipra, Girona, Spain), targeting mastitis in sheep and goat 
are available on the market. As with the other mastitis vaccine, label claim of some 
effects against S. aureus, M. heamolytica and S. aureus respectively. Highlighting the 
need for the development of an efficacious mastitis vaccines for sheep and goat. 
In the past 10 years, a wealth of knowledge on the pathogenesis of disease and 
protective immune response mechanisms against bacterial mastitis has been gained 
in ruminants. This knowledge needs to be applied in the development of an effec-
tive mastitis vaccine. Based on our current understanding of the immunological 
responses in the mammary gland of ewes against bacterial mastitis, as discussed 
above. The significant role played by antibody-mediated immune response, such 
as the importance of induction of locally produced antigen-specific IgA antibodies 
[131], and cell-mediated immune response geared towards a local Th17 response at 
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the onset of infection in preventing mastitis [87, 88, 132], supports the use of novel 
vaccines technologies in the improvement of already existing experimental vaccine. 
For example, already licensed vaccines for bacterial mastitis used in sheep and 
goats, could be improved in the following manner:
1. Inclusion of other prevalent mastitis-causing bacteria virulence factors such as 
toxins, surface proteins etc. In order to target more bacteria rather than focusing 
on one organism. For example, studies have shown that anti-leukotoxin anti-
bodies have an important role in protection against mammary infection of ru-
minants. This was demonstrated through vaccination of ewes with partially pu-
rified leukotoxin and α-haemolysin, which conferred partial protection against 
an intramammary challenge with a mastitis-causing strain of S. aureus [133].
2. Use of delivery systems (formulation strategies and novel adjuvants) in order 
to stimulate the development of immunity towards a Th17 type response 
[132, 134] and stimulate local production of IgA and IgG2 responses [135]. 
In addition, to early recruitment of neutrophils. To induce Th17 responses 
in vaccines various adjuvants have been studied. For example; S. pneumonia 
whole cell antigen vaccine formulated in aluminum hydroxide enhanced the 
quality of antibodies and Th17 CD4+ T cell response [136]. In TB infections 
Cyclic dinucleotides (CDNs) adjuvanted vaccine has be shown to elicit a Th17 
immune response correlating with enhanced protection against infections 
[137]. The bacterial components, muramyl dipeptide (MDP) a NOD2 ligand 
has been shown to induce Th17 response [138], lipopolysaccharide (LPS) a 
TLR4 ligand induces Th17 [139]. Therefore, prospective mastitis vaccine aim-
ing on eliciting a Th17 response, maybe formulated in currently used adju-
vants such as aluminum hydroxide gel in combinations with TRL ligands, 
such as TLR4 or TLR8/7 ligands; NOD2 ligands and CDNs. Alternatively, 
these ligands could also be formulated in combination with novel nanoemul-
sion oil and water adjuvants for the development of efficacious vaccine.
3. Exploring alternative vaccination routes, such as mucosal vaccine administra-
tion, in order to achieve the desired immune response, for example, in cow vacci-
nation route have an impact on the subsequent immune response [132, 140, 141]. 
For example, studies, have shown that intramammary administration of antigens 
(e.g., inactivated S. aureus) in non-lactating ewe enhance the kinetics of neutro-
phil influx with no involvement of complement in the immunological response.
4. Use of newer technologies, such as biofilm matrix polysaccharides, have also 
been used to induce protective immune response against S. aureus mastitis in 
ewes [142]. Vaccines developed using this approach offers some degree of im-
proved efficacy against S. aureus mammary infection and mastitis [143]. Mastitis 
Vaccines licensed for sheep such as, the Vimco ® vaccine based on biofilm-pro-
ducing Staphylococcus has been shown to reduce the incidence of mastitis in sheep 
[144]. In addition, omics technologies could be harnessed to fully characterize 
immunological responses in mastitis and identify relevant vaccine candidates for 
more efficacious vaccine development against mastitis causing bacteria.
5. Conclusion
Lack of effective vaccines against mastitis in sheep and goat has long been 
attributed to lack of knowledge on the disease pathogenesis and protective immune 
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response mechanism required. In the past decades, a wealth of knowledge has been 
gained on the pathological processes leading to mastitis in sheep and goat caused by 
the most prevalent pathogenic bacteria, i.e. Staphylococcus spp. Using Staphylococcus 
spp. as an example, we now know that the pathological processes leading to sub-
clinical and clinical mastitis depends on bacterial virulence factors and the induced 
host immune response. The pathogenesis of S. aureus mastitis entail three processes, 
i.e. adhesion, invasion and evasion. During these three processes S. aureus dif-
ferentially expresses virulence factors that aids colonization of the host mammary 
glands. In addition, we now have a better understanding of which virulence fac-
tors target the main cells involved in mammary immunity and how their actions 
are counteracted by the bacteria. We have also gained more understanding of the 
immune response required to limit S. aureus infection. Although we do not fully 
know the mechanisms of the protective immune response in the mammary glands 
of ruminants and still do not know how to induce such a protective response. Our 
current knowledge, points to a local protective response that most likely entail 
early recruitment of neutrophils to control bacterial inversion and IgG2 antibodies 
isotypes, and to a potential role for IgA. In addition, a local cellular response geared 
towards a Th17 immunity plays a role in bacterial cleareance and neutrophil recruit-
ment. This knowledge could be used to improve current conventional experimental 
vaccines against mastitis in small ruminants by employing immunostimulatory 
adjuvants or delivery systems capable of stimulating a local Th17 responses, by 
using TLR4, 7/8; NOD2 and CDNs ligands in adjuvant formulations.
Due to the lack of efficacy observed with conventional vaccines, research on the 
development of efficacious mastitis vaccine for small ruminant can be fast track by 
exploiting rapidly advancing omics technologies and developing immunological 
tools (reagents) for characterization of ruminant adaptive immune response in 
great detail. Reverse vaccinology approaches could be used to discover candidate 
vaccine antigens from mastitis causing bacteria. Omics technologies can also be 
applied to gain understanding on the protective adaptive immune response to 
mastitis infections by mapping relevant antigen through transcriptomics and 
proteomics, and characterizing antibody and T-cell repertoires through immuno-
proteomics. Data generated from these approach may reveal correlates of protection 
to which vaccination strategies can be based.
Conflict of interest
The author declares no conflict of interest.
Notes/Thanks/Other declarations
The author would like to thank Onderstepoort Biological Products SOC Ltd 
(OBP) and Mr Boet Weyers for support and sourcing funding. This publication was 
funded by TIA (Technology Innovation agency, South Africa) under project fund 
number TAHC12-00001.
15
Mastitis in Small Ruminants
DOI: http://dx.doi.org/10.5772/intechopen.97585
Author details
Christine T. Mwenge Kahinda*
Onderstepoort Biological Products, Onderstepoort, South Africa
*Address all correspondence to: christine@obpvaccines.co.za
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
16
Mastitis
[1] Arsenault, Julie, Pascal Dubreuil, 
Robert Higgins, and Denise Bélanger. 
"Risk factors and impacts of clinical and 
subclinical mastitis in commercial 
meat-producing sheep flocks in Quebec, 
Canada." Preventive Veterinary 
Medicine 87, no. 3-4 (2008): 373-393. 
https://doi.org/10.1016/j.
prevetmed.2008.05.006
[2] Gonzalo, C., A. Ariznabarreta, J. A. 
Carriedo, and F. San Primitivo. 
"Mammary pathogens and their 
relationship to somatic cell count and 
milk yield losses in dairy ewes." Journal 
of dairy science 85, no. 6 (2002): 
1460-1467. https://doi.org/10.3168/jds.
S0022-0302(02)74214-8
[3] Barrón-Bravo, O. G., A. J. Gutiérrez-
Chávez, C. A. Ángel-Sahagún, H. H. 
Montaldo, L. Shepard, and M. Valencia-
Posadas. "Losses in milk yield, fat and 
protein contents according to different 
levels of somatic cell count in dairy 
goats." Small Ruminant Research 113, 
no. 2-3 (2013): 421-431. https://doi.
org/10.1016/j.smallrumres.2013.04.003
[4] De Olives, Ana Martí, J. R. Díaz, M. 
P. Molina, and C. Peris. "Quantification 
of milk yield and composition changes 
as affected by subclinical mastitis 
during the current lactation in sheep." 
Journal of Dairy Science 96, no. 12 
(2013): 7698-7708. https://doi.
org/10.3168/jds.2013-6998
[5] Contreras, A., Duque Sierra, Antonio 
Sánchez, Julio César Corrales, J. C. 
Marco, M. J. Paape, and Clemente 
Gonzalo. "Mastitis in small ruminants." 
Small Ruminant Research 68, no. 1-2 
(2007): 145-153. https://doi.
org/10.1016/j.smallrumres.2006.09.011
[6] Akter, Sazeda, Md Mizanur Rahman, 
Md Abu Sayeed, Md Nurul Islam, 
Delower Hossain, Md Ahasanul Hoque, 
and Gerrit Koop. "Prevalence, aetiology 
and risk factors of subclinical mastitis in 
goats in Bangladesh." Small Ruminant 
Research 184 (2020): 106046. https://
doi.org/10.1016/j.smallrumres. 
2020.106046
[7] Berthelot X, Lagriffoul G, 
Concordet D, Barillet F, Bergonier D. 
Physiological and pathological 
thresholds of somatic cell counts in ewe 
milk. Small ruminant research. 2006 
Mar 1: 62(1-2):27-31. https://doi.
org/10.1016/j.smallrumres.2005.07.047
[8] Kiossis E, Brozos CN, Petridou E, 
Boscos C. Program for the control of 
subclinical mastitis in dairy Chios breed 
ewes during lactation. Small Ruminant 
Research. 2007 Nov 1: 73(1-3):194-199. 
https://doi.org/10.1016/j.
smallrumres.2007.01.021
[9] González-Rodríguez MC, 
Carmenes P. Evaluation of the California 
mastitis test as a discriminant method to 
detect subclinical mastitis in ewes. Small 
Ruminant Research. 1996 Jul 
1;21(3):245-250. https://doi.
org/10.1016/0921-4488(95)00826-8
[10] Bergonier, Dominique, Renée De 
Crémoux, Rachel Rupp, Gilles 
Lagriffoul, and Xavier Berthelot. 
"Mastitis of dairy small ruminants." 
Veterinary research 34, no. 5 (2003): 
689-716. https://doi.org/10.1051/
vetres:2003030
[11] Fthenakis, G.C. & Jones, J.E.T. 1990. 
The effect of experimentally induced 
subclinical mastitis on milk yield of 
ewes and on the growth of lambs. The 
British veterinary journal. 146. 43-9. 
10.1016/0007-1935(90)90075-E.
[12] Giadinis, Nektarios & Arsenos, 
Georgios & Tsakos, P. & Psychas, V. & 
Dovas, Chrysostomos & Papadopoulos, 
Elias & Karatzias, H. & Fthenakis, G.. 
2012. “Milk-drop syndrome of ewes”: 
Investigation of the causes in dairy 
sheep in Greece. Small Ruminant 
References
17
Mastitis in Small Ruminants
DOI: http://dx.doi.org/10.5772/intechopen.97585
Research. 106. 33-35. 10.1016/j.
smallrumres.2012.04.018.
[13] Knuth, R. M., Stewart, W. C., 
Taylor, J. B., Yeoman, C. J., Bisha, B., 
Page, C. M., Rowley, C. M., Lindsey, B. 
C., Van Emon, M. L., & Murphy, T. W. 
2019. Subclinical mastitis in sheep: 
etiology and association with milk 
somatic cell count and ewe productivity 
in three research flocks in the Western 
United States. Translational animal 
science, 3(Suppl 1), 1739-1743. https://
doi.org/10.1093/tas/txz078
[14] Katsafadou, A. I., Politis, A. P., 
Mavrogianni, V. S., Barbagianni, M. S., 
Vasileiou, N., Fthenakis, G. C., & 
Fragkou, I. A. (2019). Mammary 
Defences and Immunity against Mastitis 
in Sheep. Animals: an open access 
journal from MDPI, 9(10), 726. https://
doi.org/10.3390/ani9100726
[15] Giadinis, N.D., Panousis, N., 
Petridou, E.J., Siarkou, V.I., Lafi, S.Q., 
Pourliotis, K., Hatzopoulou, E. and 
Fthenakis, G.C., 2011. Selenium, 
vitamin E and vitamin A blood 
concentrations in dairy sheep flocks 
with increased or low clinical mastitis 
incidence. Small Ruminant Research, 
95(2-3), pp.193-196.
[16] Koutsoumpas, A.T., Giadinis, N.D., 
Petridou, E.J., Konstantinou, E., Brozos, 
C., Lafi, S.Q., Fthenakis, G.C. and 
Karatzias, H., 2013. Consequences of 
reduced vitamin A administration on 
mammary health of dairy ewes. Small 
ruminant research, 110(2-3), 
pp.120-123.
[17] Hogan, J.S., Weiss, W.P. and Smith, 
K.L., 1993. Role of vitamin E and 
selenium in host defense against 
mastitis. Journal of Dairy Science, 
76(9), pp.2795-2803.
[18] Olechnowicz, J. A. N., and JĘDRZEJ 
M. Jaśkowski. "Mastitis in small 
ruminants." Medycyna weterynaryjna 70, 
no. 02 (2014): 67-72. https://www.
cabdirect.org/cabdirect/search/?q=sn
%3a%220025-8628%22
[19] Mishra, A. K., Sharma, N., Singh, D. 
D., Gururaj, K., Abhishek, Kumar, V., & 
Sharma, D. K. (2018). Prevalence and 
bacterial etiology of subclinical mastitis 
in goats reared in organized farms. 
Veterinary world, 11(1), 20-24. https://
doi.org/10.14202/vetworld.2018.20-24.
[20] Islam, A., Samad, A. and Rahman, 
A.K.M.A., 2012. Prevalence of 
subclinical caprine mastitis in 
Bangladesh based on parallel 
interpretation of three screening tests. 
Int. J. Anim. Vet. Adv, 4, pp.225-228.
[21] Hussein, H.A., Fouad, M.T., Abd 
El-Razik, K.A., El-Maaty, A.M.A., 
D’Ambrosio, C., Scaloni, A. and 
Gomaa, A.M., 2020. Study on 
prevalence and bacterial etiology of 
mastitis, and effects of subclinical 
mastitis and stage of lactation on SCC in 
dairy goats in Egypt. Tropical Animal 
Health and Production, 52(6), 
pp.3091-3097.
[22] White, E.C. and Hinckley, L.S., 
1999. Prevalence of mastitis pathogens 
in goat milk. Small Ruminant Research, 
33(2), pp.117-121.
[23] Hardie J.M., Whiley R.A. 1995. The 
genus Streptococcus. In: Wood B.J.B., 
Holzapfel W.H. (eds) The Genera of 
Lactic Acid Bacteria. The Lactic Acid 
Bacteria, vol 2. Springer, Boston, MA. 
https://doi.
org/10.1007/978-1-4615-5817-0_4
[24] Mørk, T., Waage, S., Tollersrud, T. 
et al. Clinical mastitis in ewes; 
bacteriology, epidemiology and clinical 
features. Acta Vet Scand 49, 23 (2007). 
https://doi.org/10.1186/1751- 
0147-49-23
[25] G. Marogna, S. Rolesu, S. Lollai, S. 
Tola, G. Leori, Clinical findings in sheep 
farms affected by recurrent bacterial 
mastitis. Small Rumin. Res., 88 (2010), 
Mastitis
18
pp. 119-125, http://dx.doi.org/10.1016/j.
smallrumres.2009.12.019.
[26] E.M. Smith, Z.N. Willis, M. 
Blakeley, F. Lovatt, K.J. Purdy, L.E. 
Green, Bacterial species and their 
associations with acute and chronic 
mastitis in suckler ewes, Journal of 
Dairy Science, Volume 98, Issue 10, 
2015, Pages 7025-7033, ISSN 0022-0302, 
https://doi.org/10.3168/jds.2015-9702.
[27] Mavrogianni, Vasia S., Paula I. 
Menzies, Ilektra A. Fragkou, and 
George C. Fthenakis. "Principles of 
mastitis treatment in sheep and goats." 
The Veterinary clinics of North 
America. Food animal practice 27, no. 1 
(2011): 115-120.
[28] Danmallam, Faruq Ahmad, and 
Nikolai Vasilyevich Pimenov. "Study on 
prevalence, clinical presentation, and 
associated bacterial pathogens of goat 
mastitis in Bauchi, Plateau, and Edo 
states, Nigeria." Veterinary World 12, 
no. 5 (2019): 638. https://dx.doi.org/10.1
4202%2Fvetworld.2019.638-645
[29] Omaleki, Lida, Glenn F. Browning, 
Joanne L. Allen, and Stuart R. Barber. 
"The role of Mannheimia species in 
ovine mastitis." Veterinary microbiology 
153, no. 1-2 (2011): 67-72. https://doi.
org/10.1016/j.vetmic.2011.03.024
[30] Zdragas, A., P. Tsakos, C. 
Kotzamanidis, K. Anatoliotis, and I. 
Tsaknakis. "Outbreak of mastitis in ewes 
caused by Streptococcus agalactiae." 
Journal of the Hellenic Veterinary 
Medical Society 56, no. 2 (2005): 
114-121.
[31] Contreras, G. Andres, and Juan 
Miguel Rodríguez. "Mastitis: 
comparative etiology and 
epidemiology." Journal of mammary 
gland biology and neoplasia 16, no. 4 
(2011): 339-356.
[32] Koop, G., J. F. Rietman, and M. C. 
Pieterse. "Staphylococcus aureus 
mastitis in Texel sheep associated with 
suckling twins." Veterinary record 167 
(2010): 868-869.
[33] Bonnefont, Cécile MD, Mehdi 
Toufeer, Cécile Caubet, Eliane Foulon, 
Christian Tasca, Marie-Rose Aurel, 
Dominique Bergonier et al. 
"Transcriptomic analysis of milk 
somatic cells in mastitis resistant and 
susceptible sheep upon challenge with 
Staphylococcus epidermidis and 
Staphylococcus aureus." BMC genomics 12, 
no. 1 (2011): 208.
[34] Onni, Toniangelo, Giovanna Sanna, 
Jesper Larsen, and Sebastiana Tola. 
"Antimicrobial susceptibilities and 
population structure of Staphylococcus 
epidermidis associated with ovine 
mastitis." Veterinary microbiology 148, 
no. 1 (2011): 45-50.
[35] Zdragas (Α. Ζδραγκασ), A., Tsakos 
(Π. Τσακοσ), P., Kotzamanidis (Χ. 
Κοτζαμανιδησ), C., Anatoliotis (Κ. 
Ανατολιωτησ), K., & Tsaknakis (Η. 
Τσακνακησ), I. (2017). Outbreak of 
mastitis in ewes caused by Streptococcus 
agalactiae. Journal of the Hellenic 
Veterinary Medical Society, 56(2), 
114-121. Doi:Https://Doi.Org/10.12681/
Jhvms.15075
[36] Las Heras, A., Vela, A.I., Fernández, 
E., Legaz, E., Domínguez, L. and 
Fernández-Garayzábal, J.F., 2002. 
Unusual outbreak of clinical mastitis in 
dairy sheep caused by Streptococcus 
equi subsp. zooepidemicus. Journal of 
clinical microbiology, 40(3), 
pp.1106-1108.
[37] Kern, Gesche, Imke Traulsen, Nicole 
Kemper, and Joachim Krieter. "Analysis 
of somatic cell counts and risk factors 
associated with occurrence of bacteria 
in ewes of different primary purposes." 
Livestock Science 157, no. 2-3 (2013): 
597-604.
[38] N.G.C. Vasileiou, P.J. Cripps, K.S. 
Ioannidi, D.C. Chatzopoulos, D.A. 
19
Mastitis in Small Ruminants
DOI: http://dx.doi.org/10.5772/intechopen.97585
Gougoulis, S. Sarrou, D.C. Orfanou, A.P. 
Politis, T. Calvo Gonzalez-Valerio, S. 
Argyros, V.S. Mavrogianni, E. Petinaki, 
G.C. Fthenakis. Extensive countrywide 
field investigation of subclinical mastitis 
in sheep in Greece. Journal of Dairy 
Science, Volume 101, Issue 8, 2018, 
Pages 7297-7310, ISSN 0022-0302, 
https://doi.org/10.3168/jds.2017-14075. 
(https://www.sciencedirect.com/
science/article/pii/S0022030218305319)
[39] Line Svennesen, Søren S. Nielsen, 
Yasser S. Mahmmod, Volker Krömker, 
Karl Pedersen, Ilka C. Klaas. 2019. 
Association between teat skin 
colonization and intramammary 
infection with Staphylococcus aureus 
and Streptococcus agalactiae in herds 
with automatic milking systems, Journal 
of Dairy Science, Volume 102, Issue 1, 
Pages 629-639, ISSN 0022-0302, https://
doi.org/10.3168/jds.2018-15330. 
(https://www.sciencedirect.com/
science/article/pii/S0022030218310609)
[40] Keefe, G., 2012. Update on control 
of Staphylococcus aureus and 
Streptococcus agalactiae for 
management of mastitis. Veterinary 
Clinics: Food Animal Practice, 28(2), 
pp.203-216.
[41] Machado, Gustavo. 2018. mastitis-
in-small-ruminants. Animal Husbandry, 
Dairy and Veterinary Science. 2. 
10.15761/AHDVS.1000144.
[42] McDonald, Thomas L., Marilynn A. 
Larson, David R. Mack, and Annika 
Weber. "Elevated extrahepatic 
expression and secretion of mammary-
associated serum amyloid A 3 
(M-SAA3) into colostrum." Veterinary 
immunology and immunopathology 83, 
no. 3-4 (2001): 203-211. https://doi.
org/10.1016/S0165-2427(01)00380-4
[43] Omar, Syaliza. (2018). Isolation and 
identification of common bacteria 
causing subclinical mastitis in dairy 
goats. International Food Research 
Journal. 25. 1668-1674.
[44] Gelasakis, A. I., Angelidis, A. S., 
Giannakou, R., Filioussis, G., Kalamaki, 
M. S., & Arsenos, G. (2016). Bacterial 
subclinical mastitis and its effect on 
milk yield in low-input dairy goat herds. 
Journal of dairy science, 99(5), 3698-
3708. https://doi.org/10.3168/
jds.2015-10694
[45] Ribeiro, M.G., Lara, G.H.B., Bicudo, 
S.D., Souza, A.V.G., Salerno, T., 
Siqueira, A.K., & Geraldo, J.S. (2007). 
An unusual gangrenous goat mastitis 
caused by Staphylococcus aureus, 
Clostridium perfringens and Escherichia 
coli co-infection. Arquivo Brasileiro de 
Medicina Veterinária e Zootecnia, 59(3), 
810-812. https://dx.doi.org/10.1590/
S0102-09352007000300037
[46] Min, B., Tomita, G., & Hart, S. 
(2007). Effect of subclinical 
intramammary infection on somatic cell 
counts and chemical composition of 
goats' milk. Journal of Dairy Research, 
74(2), 204-210. doi:10.1017/
S0022029906002378
[47] Kalin Hristov, Teodora Popova, 
Roman Pepovich and Branimir Nikolov. 
2016. Characterization of Microbial 
Causative Agents of Subclinical Mastitis 
in Goats in Bulgaria. Int.J.Curr.
Microbiol.App.Sci. 5(8): 316-323. doi: 
http://dx.doi.org/10.20546/
ijcmas.2016.508.034
[48] Salvatore Virdis, Christian Scarano, 
Francesca Cossu, Vincenzo Spanu, Carlo 
Spanu, Enrico Pietro Luigi De Santis, 
2010. Antibiotic Resistance in 
Staphylococcus aureus and Coagulase 
Negative Staphylococci Isolated from 
Goats with Subclinical Mastitis. 
Veterinary Medicine International, vol. 
2010, Article ID 517060, 6 pages. 
https://doi.org/10.4061/2010/517060
[49] Marogna, G., Pilo, C., Vidili, A., 
Tola, S., Schianchi, G. and Leori, S.G., 
2012. Comparison of clinical findings, 
microbiological results, and farming 
parameters in goat herds affected by 
Mastitis
20
recurrent infectious mastitis. Small 
Ruminant Research, 102(1), pp.74-83.
[50] Spuria, L., Biasibetti, E., Bisanzio, 
D., Biasato, I., De Meneghi, D., Nebbia, 
P., Robino, P., Bianco, P., Lamberti, M., 
Caruso, C. and Di Blasio, A., 2017. 
Microbial agents in macroscopically 
healthy mammary gland tissues of small 
ruminants. PeerJ, 5, p.e3994.
[51] Jakeen K. El-Jakee, Noha E. Aref, 
Alaa Gomaa, Mahmoud D. El-Hariri, 
Hussein M. Galal, Sherif A. Omar, 
Ahmed Samir, 2013. Emerging of 
coagulase negative staphylococci as a 
cause of mastitis in dairy animals: An 
environmental hazard, International 
Journal of Veterinary Science and 
Medicine, Volume 1, Issue 2, Pages 
74-78, ISSN 2314-4599, https://doi.
org/10.1016/j.ijvsm.2013.05.006.
[52] Ehrenberg, A. & Sobiraj, A. & 
Vázquez, Hugo & El-Sayed, Amr & 
Castañeda Vazquez, Martha & Zschöck, 
Michael. (2020). Characterization of 
Coagulase Negative Staphylococci 
Isolated from Dairy Goats in Germany. 
Journal of Animal and Veterinary 
Advances. 19. 1-10. 10.36478/
javaa.2020.1.10.
[53] Condas, L.A., De Buck, J., Nobrega, 
D.B., Carson, D.A., Naushad, S., De 
Vliegher, S., Zadoks, R.N., Middleton, 
J.R., Dufour, S., Kastelic, J.P. and 
Barkema, H.W., 2017. Prevalence of 
non-aureus staphylococci species 
causing intramammary infections in 
Canadian dairy herds. Journal of dairy 
science, 100(7), pp.5592-5612.
[54] Gosselin, V.B., Lovstad, J., Dufour, 
S., Adkins, P.R. and Middleton, J.R., 
2018. Use of MALDI-TOF to 
characterize staphylococcal 
intramammary infections in dairy goats. 
Journal of dairy science, 101(7), 
pp.6262-6270.
[55] Gosselin, V.B., Dufour, S., Adkins, 
P.R. and Middleton, J.R., 2019. 
Persistence of coagulase negative 
staphylococcal intramammary 
infections in dairy goats. The Journal of 
dairy research, 86(2), pp.211-216.
[56] Ruegg, P.L., 2009. The quest for the 
perfect test: phenotypic versus 
genotypic identification of coagulase-
negative staphylococci associated with 
bovine mastitis. Veterinary 
microbiology, 134(1-2), pp.15-19.
[57] Liesenborghs, L., Verhamme, P. and 
Vanassche, T., 2018. Staphylococcus 
aureus, master manipulator of the 
human hemostatic system. Journal of 
Thrombosis and Haemostasis, 16(3), 
pp.441-454.
[58] Turchi, B., Bertelloni, F., Marzoli, 
F., Cerri, D., Tola, S., Azara, E., 
Longheu, C.M., Tassi, R., Schiavo, M., 
Cilia, G. and Fratini, F., 2020. Coagulase 
negative staphylococci from ovine milk: 
Genotypic and phenotypic 
characterization of susceptibility to 
antibiotics, disinfectants and biofilm 
production. Small Ruminant Research, 
183, p.106030.
[59] Barbara Turchi, Fabrizio Bertelloni, 
Filippo Marzoli, Domenico Cerri, 
Sebastiana Tola, Elisa Azara, Carla 
Maria Longheu, Riccardo Tassi, Martina 
Schiavo, Giovanni Cilia, Filippo Fratini. 
2020. Coagulase negative staphylococci 
from ovine milk: Genotypic and 
phenotypic characterization of 
susceptibility to antibiotics, 
disinfectants and biofilm production, 
Small Ruminant Research, Volume 183, 
106030, ISSN 0921-4488, https://doi.
org/10.1016/j.smallrumres.2019.106030.
[60] Côté-Gravel, J. and Malouin, F., 
2019. Symposium review: features of 
Staphylococcus aureus mastitis 
pathogenesis that guide vaccine 
development strategies. Journal of dairy 
science, 102(5), pp.4727-4740.
[61] O’Riordan, K., & Lee, J. C. (2004). 
Staphylococcus aureus capsular 
21
Mastitis in Small Ruminants
DOI: http://dx.doi.org/10.5772/intechopen.97585
polysaccharides. Clinical microbiology 
reviews, 17(1), 218-234. Doi :10.1128/
cmr.17.1.218-234.2004.
[62] Mistretta, N., Brossaud, M., Telles, 
F. et al. Glycosylation of Staphylococcus 
aureus cell wall teichoic acid is 
influenced by environmental 
conditions. Sci Rep 9, 3212 (2019) 
doi:10.1038/s41598-019-39929-1.
[63] Liu, G. Molecular Pathogenesis of 
Staphylococcus aureus Infection. Pediatr 
Res 65, 71-77 (2009) doi:10.1203/
PDR.0b013e31819dc44d
[64] O. Kerro Dego, J.E. van Dijk & H. 
Nederbragt (2002) Factors involved in 
the early pathogenesis of bovine 
Staphylococcus aureus mastitis with 
emphasis on bacterial adhesion and 
invasion. A review, Veterinary 
Quarterly, 24:4, 181-198, DOI:10.1080/0
1652176.2002.9695135
[65] Melchior, M. B., H. Vaarkamp, and J. 
Fink-Gremmels. "Biofilms: a role in 
recurrent mastitis infections?" The 
Veterinary Journal 171, no. 3 (2006): 
398-407.
[66] Hathroubi, S., M. A. Mekni, P. 
Domenico, D. Nguyen, and M. Jacques. 
2017. Biofilms: Microbial Shelters 
Against Antibiotics. Microb. Drug 
Resist. 23:147-156. https://doi.
org/10.1089/mdr.2016.0087.
[67] Lorraine M. Sordillo. 2005. Factors 
affecting mammary gland immunity 
and mastitis susceptibility, Livestock 
Production Science, Volume 98, Issues 
1-2, Pages 89-99, ISSN 0301-6226, 
https://doi.org/10.1016/j.
livprodsci.2005.10.017
[68] Rainard, Pascal & Riollet, Céline. 
(2006). Innate immunity of bovine 
mammary gland. Veterinary research. 
37. 369-400. 10.1051/vetres:2006007.
[69] Katsafadou, Angeliki I.; Politis, 
Antonis P.; Mavrogianni, Vasia S.; 
Barbagianni, Mariana S.; Vasileiou, 
Natalia G.C.; Fthenakis, George C.; 
Fragkou, Ilektra A. 2019. "Mammary 
Defences and Immunity against Mastitis 
in Sheep" Animals 9, no. 10: 726. https://
doi.org/10.3390/ani9100726
[70] Javier Oviedo-Boyso, Juan J. Valdez-
Alarcón, Marcos Cajero-Juárez, 
Alejandra Ochoa-Zarzosa, Joel E. 
López-Meza, Alejandro Bravo-Patiño, 
Víctor M. Baizabal-Aguirre. 2007. Innate 
immune response of bovine mammary 
gland to pathogenic bacteria responsible 
for mastitis, Journal of Infection, 
Volume 54, Issue 4, Pages 399-409, ISSN 
0163-4453, https://doi.org/10.1016/j.
jinf.2006.06.010.
[71] Zecchinon, Laurent, Thomas Fett, 
and Daniel Desmecht. "How 
Mannheimia haemolytica defeats host 
defence through a kiss of death 
mechanism." Veterinary research 36, no. 
2 (2005): 133-156.
[72] Berhanu, Gemechu. (2020). 
Virulence Factors and Pathogenesis of 
Some Streptococcus Species. 6. 1-10.
[73] Mohamed Ezzat Alnakip, Marcos 
Quintela-Baluja, Karola Böhme, 
Inmaculada Fernández-No, Sonia 
Caamaño-Antelo, Pillar Calo-Mata, 
Jorge Barros-Velázquez, 2014. "The 
Immunology of Mammary Gland of 
Dairy Ruminants between Healthy and 
Inflammatory Conditions", Journal of 
Veterinary Medicine, vol. 2014, Article 
ID 659801, 31 pages. https://doi.
org/10.1155/2014/659801
[74] Brenaut, P., Lefèvre, L., Rau, A., 
Laloë, D., Pisoni, G., Moroni, P., 
Bevilacqua, C., & Martin, P. (2014). 
Contribution of mammary epithelial 
cells to the immune response during 
early stages of a bacterial infection to 
Staphylococcus aureus. Veterinary 
research, 45(1), 16. https://doi.
org/10.1186/1297-9716-45-16
[75] Petzl, Wolfram, Holm Zerbe, Juliane 
Günther, Wei Yang, Hans-Martin 
Mastitis
22
Seyfert, Gerd Nürnberg, and Hans-
Joachim Schuberth. "Escherichia coli, 
but not Staphylococcus aureus triggers 
an early increased expression of factors 
contributing to the innate immune 
defense in the udder of the cow." 
Veterinary research 39, no. 2 
(2008): 1-23.
[76] Takeda, K. and Akira, S., 2005. 
Toll-like receptors in innate immunity. 
International immunology, 17(1), 
pp.1-14.
[77] Rainard P, Riollet C. Innate 
immunity of the bovine mammary 
gland. Vet Res. 2006 May-
Jun;37(3):369-400. doi: 10.1051/
vetres:2006007. Epub 2006 Feb 23. 
PMID: 16611554.
[78] Addis, Maria Filippa, Salvatore 
Pisanu, Gavino Marogna, Tiziana 
Cubeddu, Daniela Pagnozzi, Carla 
Cacciotto, Franca Campesi, Giuseppe 
Schianchi, Stefano Rocca, and Sergio 
Uzzau. "Production and release of 
antimicrobial and immune defense 
proteins by mammary epithelial cells 
following Streptococcus uberis infection 
of sheep." Infection and immunity 81, 
no. 9 (2013): 3182-3197. DOI: 10.1128/
IAI.00291-13
[79] Van Harten, R.M., Van 
Woudenbergh, E., Van Dijk, A. and 
Haagsman, H.P., Cathelicidins: 
immunomodulatory antimicrobials. 
Vaccines, 6(3) (2018): p.63. https://doi.
org/10.3390/vaccines6030063
[80] Sladek, Z. and Rysanek, D., 2001. 
Neutrophil apoptosis during the 
resolution of bovine mammary gland 
injury. Research in Veterinary Science, 
70(1), pp.41-46.
[81] Prin-Mathieu, C., Le Roux, Y., 
Faure, G.C., Laurent, F., Bene, M.C. and 
Moussaoui, F., 2002. Enzymatic 
activities of bovine peripheral blood 
leukocytes and milk polymorphonuclear 
neutrophils during intramammary 
inflammation caused by 
lipopolysaccharide. Clinical and 
Diagnostic Laboratory Immunology, 
9(4), pp.812-817.
[82] Politis, I., Zhao, X., McBride, B.W. 
and Burton, J.H., 1992. Function of 
bovine mammary macrophages as 
antigen-presenting cells. Veterinary 
immunology and immunopathology, 
30(4), pp.399-410.
[83] Denis, M., Parlane, N.A., Lacy-
Hulbert, S.J., Summers, E.L., Buddle, 
B.M. and Wedlock, D.N., 2006. 
Bactericidal activity of macrophages 
against Streptococcus uberis is different 
in mammary gland secretions of 
lactating and drying off cows. 
Veterinary immunology and 
immunopathology, 114(1-2), 
pp.111-120.
[84] Swiderek, W.P., Charon, K.M., 
Winnicka, A.N.N.A. and Gruszczynska, 
J., 2006. Relationship between blood 
lymphocyte phenotype, drb1 (mhc class 
ii) gene polymorphism and somatic cell 
count in ewe milk. BULLETIN-
VETERINARY INSTITUTE IN 
PULAWY, 50(1), p.73.
[85] Lawand Myriam, Déchanet-Merville 
Julie, Dieu-Nosjean Marie-Caroline. 
2017. Key Features of Gamma-Delta 
T-Cell Subsets in Human Diseases and 
Their Immunotherapeutic Implications, 
Frontiers in Immunology, Vol. 8, 
DOI=10.3389/fimmu.2017.00761, 
ISSN=1664-3224. https://www.
frontiersin.org/article/10.3389/
fimmu.2017.00761
[86] Alehegne Yirsaw, Cynthia L. 
Baldwin, 2021. Goat γδ T cells, 
Developmental & Comparative 
Immunology, Volume 114, 103809, ISSN 
0145-305X, https://doi.org/10.1016/j.
dci.2020.103809
[87] Jing XQ, Cao DY, Liu H, Wang XY, 
Zhao XD, Chen DK. 2012. Pivotal Role 
of IL-17-producing gamma delta T cells 
23
Mastitis in Small Ruminants
DOI: http://dx.doi.org/10.5772/intechopen.97585
in Mouse chronic mastitis 
experimentally induced with 
Staphylococcus aureus. Asian J Anim Vet 
Adv, 7(12):1266-1278. https://doi.
org/10.3923/ajava .2012.1266.1278 22
[88] Zhao Y, Zhou M, Gao Y, Liu H, 
Yang W, Yue J, Chen D. (2015) Shifted T 
Helper Cell Polarization in a Murine 
Staphylococcus aureus Mastitis Model. 
PLoS ONE 10(7): e0134797. doi:10.1371/
journal. pone.0134797
[89] Burton, Jeanne & Erskine, Ronald. 
2003. Immunity and mastitis: Some new 
ideas for an old disease. The Veterinary 
clinics of North America. Food animal 
practice. 19. 1-45, v. 10.1016/
S0749-0720(02)00073-7.
[90] Vautor, Eric, Hélène Carsenti-
Dellamonica, Michele Sabah, Géraldine 
Mancini, Michel Pépin, and Pierre 
Dellamonica. "Characterization of 
Staphylococcus aureus isolates 
recovered from dairy sheep farms (agr 
group, adherence, slime, resistance to 
antibiotics)." Small Ruminant Research 
72, no. 2-3 (2007): 197-199.
[91] Posner, M.G., Upadhyay, A., 
Abubaker, A.A., Fortunato, T.M., Vara, 
D., Canobbio, I., Bagby, S. and Pula, G., 
2016. Extracellular fibrinogen-binding 
protein (Efb) from Staphylococcus 
aureus inhibits the formation of 
platelet-leukocyte complexes. Journal of 
Biological Chemistry, 291(6), 
pp.2764-2776.
[92] Postma, B., Poppelier, M.J., Van 
Galen, J.C., Prossnitz, E.R., Van Strijp, 
J.A., De Haas, C.J. and Van Kessel, K.P., 
2004. Chemotaxis inhibitory protein of 
Staphylococcus aureus binds specifically 
to the C5a and formylated peptide 
receptor. The Journal of Immunology, 
172(11), pp.6994-7001.
[93] Di, AL Carlo, M. J. Paape, and R. H. 
Miller. "Reactivity of purified 
complement component 3b with bovine 
neutrophils and modulation of 
complement receptor 1." American 
journal of veterinary research 57, no. 2 
(1996): 151-156.
[94] Cunnion, K. M., J. C. Lee, and M. 
M. Frank. "Capsule production and 
growth phase influence binding of 
complement to Staphylococcus aureus." 
Infection and immunity 69, no. 11 
(2001): 6796-6803.
[95] Pozzi C, Lofano G, Mancini F, 
Soldaini E, Speziale P, De Gregorio E, 
Rappuoli R, Bertholet S, Grandi G, 
Bagnoli F. 2015. Phagocyte subsets and 
lymphocyte clonal deletion behind 
ineffective immune response to 
Staphylococcus aureus. FEMS Microbiol 
Rev. ;39(5):750-763. doi: 10.1093/
femsre/fuv024. Epub 2015 May 19. 
PMID: 25994610.
[96] Rainard, P., Gitton, C., Chaumeil, T. 
et al. Host factors determine the 
evolution of infection with 
Staphylococcus aureus to gangrenous 
mastitis in goats. Vet Res 49, 72 (2018). 
https://doi.org/10.1186/
s13567-018-0564-4
[97] Hughes, K., Watson, C.J. The 
Mammary Microenvironment in 
Mastitis in Humans, Dairy Ruminants, 
Rabbits and Rodents: A One Health 
Focus. J Mammary Gland Biol Neoplasia 
23, 27-41 (2018). https://doi.
org/10.1007/s10911-018-9395-1
[98] Bulgari, O., Dong, X., Roca, A.L., 
Caroli, A.M. and Loor, J.J., 2017. Innate 
immune responses induced by 
lipopolysaccharide and lpoteichoic acid 
in primary goat mammary epithelial 
cells. Journal of animal science and 
biotechnology, 8(1), pp.1-10.
[99] Katsafadou, Angeliki I., George Th 
Tsangaris, Athanasios K. 
Anagnostopoulos, Charalambos Billinis, 
Mariana S. Barbagianni, Natalia GC 
Vasileiou, Stavros A. Spanos, Vasia S. 
Mavrogianni, and George C. Fthenakis. 
"Differential quantitative proteomics 
Mastitis
24
study of experimental Mannheimia 
haemolytica mastitis in sheep." Journal 
of proteomics 205 (2019): 103393.
[100] Brenaut, Pauline, Lucas Lefèvre, 
Andrea Rau, Denis Laloë, Giuliano 
Pisoni, Paolo Moroni, Claudia 
Bevilacqua, and Patrice Martin. 
"Contribution of mammary epithelial 
cells to the immune response during 
early stages of a bacterial infection to 
Staphylococcus aureus." Veterinary 
research 45, no. 1 (2014): 16. https://doi.
org/10.1186/1297-9716-45-16
[101] Cubeddu, Tiziana, Carla Cacciotto, 
Salvatore Pisanu, Vittorio Tedde, 
Alberto Alberti, Marco Pittau, Simone 
Dore et al. "Cathelicidin production and 
release by mammary epithelial cells 
during infectious mastitis." Veterinary 
immunology and immunopathology 189 
(2017): 66-70. https://doi.org/10.1016/j.
vetimm.2017.06.002
[102] Scheenstra, M.R., van Harten, 
R.M., Veldhuizen, E.J., Haagsman, H.P. 
and Coorens, M., 2020. Cathelicidins 
modulate TLR-activation and 
inflammation. Frontiers in Immunology, 
11, p.1137.
[103] Gurao A, Kashyap SK, Singh R 
(2017) β-defensins: An innate defense 
for bovine mastitis, Veterinary World, 
10(8): 990-998.
[104] Jonas Bystrom, Taher E. Taher, M. 
Sherwan Muhyaddin, Felix I. Clanchy, 
Pamela Mangat, Ali S. Jawad, Richard O. 
Williams, Rizgar A. Mageed, 2015. 
"Harnessing the Therapeutic Potential 
of Th17 Cells", Mediators of 
Inflammation, vol. 2015, Article ID 
205156, 11 pages. https://doi.
org/10.1155/2015/205156
[105] Ouyang, W., Kolls, J.K. and Zheng, 
Y., 2008. The biological functions of T 
helper 17 cell effector cytokines in 
inflammation. Immunity, 28(4), 
pp.454-467.
[106] Mitchell, R.E., Hassan, M., Burton, 
B.R., Britton, G., Hill, E.V., Verhagen, J. 
and Wraith, D.C., 2017. IL-4 enhances 
IL-10 production in Th1 cells: 
implications for Th1 and Th2 regulation. 
Scientific reports, 7(1), pp.1-14.
[107] Gu, Y., Yang, J., Ouyang, X., Liu, 
W., Li, H., Yang, J., Bromberg, J., Chen, 
S.H., Mayer, L., Unkeless, J.C. and 
Xiong, H., 2008. Interleukin 10 
suppresses Th17 cytokines secreted by 
macrophages and T cells. European 
journal of immunology, 38(7), 
pp.1807-1813.
[108] A. Lacoma, V. Cano, D. Moranta, V. 
Regueiro, D. Domínguez-Villanueva, M. 
Laabei, M. González-Nicolau, V. Ausina, 
C. Prat & J. A. Bengoechea (2017) 
Investigating intracellular persistence of 
Staphylococcus aureus within a murine 
alveolar macrophage cell line, Virulence, 
8:8, 1761-1775, DOI: 
10.1080/21505594.2017.1361089
[109] Flannagan, R. S., Heit, B., and 
Heinrichs, D. E. (2016) Intracellular 
replication of Staphylococcus aureus in 
mature phagolysosomes in macrophages 
precedes host cell death, and bacterial 
escape and dissemination. Cellular 
Microbiology, 18: 514-535. Doi: 10.1111/
cmi.12527.
[110] Bröker, B. M., Mrochen, D., & 
Péton, V. (2016). The T Cell Response to 
Staphylococcus aureus. Pathogens 
(Basel, Switzerland), 5(1), 31. https://
doi.org/10.3390/pathogens5010031
[111] Norcross, N.L., 1991. Specific 
defence mechanisms of the udder. 
Vlaams Diergeneeskundig Tijdschrift 
(Belgium). special issue.
[112] Hine, B.C., Hunt, P.W., Beasley, 
A.M., Windon, R.G., Glover, S.A. and 
Colditz, I.G., 2010. Selective transport 
of IgE into ovine mammary secretions. 
Research in veterinary science, 89(2), 
pp.184-190.
25
Mastitis in Small Ruminants
DOI: http://dx.doi.org/10.5772/intechopen.97585
[113] Katsafadou, A.I., Politis, A.P., 
Mavrogianni, V.S., Barbagianni, M.S., 
Vasileiou, N.G., Fthenakis, G.C. and 
Fragkou, I.A., 2019. Mammary defences 
and immunity against mastitis in sheep. 
Animals, 9(10), p.726. https://doi.
org/10.3390/ani9100726
[114] Queiroga M. C. (2018). Local and 
systemic humoral response to ovine 
mastitis caused by Staphylococcus 
epidermidis. SAGE open medicine, 6, 
2050312118801466. https://doi.
org/10.1177/2050312118801466
[115] Barrio, M.B., Rainard, P. and 
Poutrel, B., 2003. Milk complement and 
the opsonophagocytosis and killing of 
Staphylococcus aureus mastitis isolates 
by bovine neutrophils. Microbial 
pathogenesis, 34(1), pp.1-9. https://doi.
org/10.1016/S0882-4010(02)00186-9
[116] Nagasawa, Y., Kiku, Y., Sugawara, 
K. et al. Staphylococcus aureus-specific 
IgA antibody in milk suppresses the 
multiplication of S. aureus in infected 
bovine udder. BMC Vet Res 15, 286 
(2019). https://doi.org/10.1186/
s12917-019-2025-3
[117] Johler, S., Weder, D., Bridy, C., 
Huguenin, M.C., Robert, L., 
Hummerjohann, J. and Stephan, R., 
2015. Outbreak of staphylococcal food 
poisoning among children and staff at a 
Swiss boarding school due to soft cheese 
made from raw milk. Journal of dairy 
science, 98(5), pp.2944-2948.
[118] Obaidat, M.M., Salman, A.E.B. and 
Roess, A.A., 2018. High prevalence and 
antimicrobial resistance of mecA 
Staphylococcus aureus in dairy cattle, 
sheep, and goat bulk tank milk in 
Jordan. Tropical animal health and 
production, 50(2), pp.405-412.
[119] van den Brom, R., de Jong, A., van 
Engelen, E., Heuvelink, A. and Vellema, 
P., 2020. Zoonotic risks of pathogens 
from sheep and their milk borne 
transmission. Small Ruminant Research, 
189, p.106123.
[120] Ribeiro Júnior, J.C., Silva, F.F., 
Lima, J.B.A., Ossugui, E.H., Teider 
Junior, P.I., Campos, A.C.L.P., Navarro, 
A., Tamanini, R., Ribeiro, J., Alfieri, 
A.A. and Beloti, V., 2019. Molecular 
characterization and antimicrobial 
resistance of pathogenic Escherichia coli 
isolated from raw milk and Minas 
Frescal cheeses in Brazil. Journal of 
dairy science.
[121] Baylis, C.L., 2009. Raw milk and 
raw milk cheeses as vehicles for 
infection by Verocytotoxin-producing 
Escherichia coli. International Journal 
of Dairy Technology, 62(3), 
pp.293-307.
[122] McKellar, Q. A. "The health of the 
sheep industry and the medicines to 
maintain it." Small Ruminant Research 
62, no. 1-2 (2006): 7-12. https://doi.
org/10.1016/j.smallrumres.2005.07.027
[123] Vasileiou, N.G.C., Cripps, P.J., 
Ioannidi, K.S., Katsafadou, A.I., 
Chatzopoulos, D.C., Barbagianni, M.S., 
Tsioli, V., Dermisiadou, E., Karavanis, 
E., Papadopoulos, N. and Lianou, D.T., 
2019. Experimental study for evaluation 
of the efficacy of a biofilm-embedded 
bacteria-based vaccine against 
Staphylococcus chromogenes-associated 
mastitis in sheep. Veterinary 
microbiology, 239, p.108480.
[124] Longheu, C.M., Azara, E., 
Marogna, G., Addis, M.F. and Tola, S., 
2020. Identification of secreted and 
cellular antigens of Staphylococcus 
aureus causing dairy sheep mastitis and 
their potential for vaccine development. 
Veterinary Immunology and 
Immunopathology, 230, p.110149.
[125] Loera-Muro, A., Guerrero-Barrera, 
A., Tremblay DN, Y., Hathroubi, S. and 
Angulo, C., 2021. Bacterial biofilm-
derived antigens: a new strategy for 
Mastitis
26
vaccine development against infectious 
diseases. Expert Review of Vaccines.
[126] Tollersrud, T., Nørstebø, P.E., 
Engvik, J.P., Andersen, S.R., Reitan, L.J. 
and Lund, A., 2002. Antibody responses 
in sheep vaccinated against 
Staphylococcus aureus mastitis: a 
comparison of two experimental 
vaccines containing different adjuvants. 
Veterinary research communications, 
26(8), pp.587-600.
[127] 127: Middleton, J.R., Luby, C.D. 
and Adams, D.S., 2009. Efficacy of 
vaccination against staphylococcal 
mastitis: a review and new data. 
Veterinary microbiology, 134(1-2), 
pp.192-198.
[128] Piepers, S., Prenafeta, A., Verbeke, 
J., De Visscher, A., March, R. and De 
Vliegher, S., 2017. Immune response 
after an experimental intramammary 
challenge with killed Staphylococcus 
aureus in cows and heifers vaccinated 
and not vaccinated with Startvac, a 
polyvalent mastitis vaccine. Journal of 
dairy science, 100(1), pp.769-782.
[129] Schukken, Y.H., Bronzo, V., 
Locatelli, C., Pollera, C., Rota, N., 
Casula, A., Testa, F., Scaccabarozzi, L., 
March, R., Zalduendo, D. and Guix, R., 
2014. Efficacy of vaccination on 
Staphylococcus aureus and coagulase-
negative staphylococci intramammary 
infection dynamics in 2 dairy herds. 
Journal of dairy science, 97(8), 
pp.5250-5264.
[130] Dego, O.K., 2020. Current Status of 
Antimicrobial Resistance and Prospect 
for New Vaccines against Major Bacterial 
Bovine Mastitis Pathogens. In Animal 
Reproduction in Veterinary Medicine. 
IntechOpen.
[131] Nagasawa, Y., Kiku, Y., Sugawara, 
K., Hirose, A., Kai, C., Kitano, N., 
Takahashi, T., Nochi, T., Aso, H., 
Sawada, S.I. and Akiyoshi, K., 2019. 
Staphylococcus aureus-specific IgA 
antibody in milk suppresses the 
multiplication of S. aureus in infected 
bovine udder. BMC veterinary research, 
15(1), pp.1-14.
[132] Cebron, N., Maman, S., 
Walachowski, S. et al. 2020. Th17-
related mammary immunity, but not a 
high systemic Th1 immune response is 
associated with protection against E. 
coli mastitis. Npj Vaccines 5, 108 . 
https://doi.org/10.1038/
s41541-020-00258-4
[133] Vidal, G. and Bezard, G., 1968. 
Vaccination avec la leucocidine dans la 
mammite staphylococcique de la brebis. 
In Annales de Biologie Animale Biochimie 
Biophysique (Vol. 8, No. 2, pp. 291-299). 
EDP Sciences.
[134] Rainard, P., Cunha, P., Martins, 
R.P., Gilbert, F.B., Germon, P. and 
Foucras, G., 2020. Type 3 immunity: a 
perspective for the defense of the 
mammary gland against infections. 
Veterinary Research, 51(1), pp.1-8.
[135] Yoshii, K., Hosomi, K., 
Shimoyama, A., Wang, Y., Yamaura, H., 
Nagatake, T., Suzuki, H., Lan, H., 
Kiyono, H., Fukase, K. and Kunisawa, J., 
2020. Chemically Synthesized 
Alcaligenes Lipid A Shows a Potent and 
Safe Nasal Vaccine Adjuvant Activity for 
the Induction of Streptococcus 
pneumoniae-Specific IgA and Th17 
Mediated Protective Immunity. 
Microorganisms, 8(8), p.1102.
[136] HogenEsch, H., Dunham, A., 
Hansen, B. et al. 2011. Formulation of a 
killed whole cell pneumococcus vaccine 
- effect of aluminum adjuvants on the 
antibody and IL-17 response. J Immune 
Based Ther Vaccines 9, 5. https://doi.
org/10.1186/1476-8518-9-5
[137] Van Dis, E., Sogi, K. M., Rae, C. S., 
Sivick, K. E., Surh, N. H., Leong, M. L., 
Kanne, D. B., Metchette, K., Leong, J. J., 
Bruml, J. R., Chen, V., Heydari, K., 
Cadieux, N., Evans, T., McWhirter, S. 
27
Mastitis in Small Ruminants
DOI: http://dx.doi.org/10.5772/intechopen.97585
M., Dubensky, T. W., Jr, Portnoy, D. A., 
& Stanley, S. A. 2018. STING-Activating 
Adjuvants Elicit a Th17 Immune 
Response and Protect against 
Mycobacterium tuberculosis Infection. 
Cell reports, 23(5), 1435-1447. https://
doi.org/10.1016/j.celrep.2018.04.003
[138] Manni, M., Ding, W., Stohl, L.L. 
and Granstein, R.D., 2011. Muramyl 
dipeptide induces Th17 polarization 
through activation of endothelial cells. 
The Journal of Immunology, 186(6), 
pp.3356-3363.
[139] Park JH, Jeong SY, Choi AJ, Kim SJ. 
2015. Lipopolysaccharide directly 
stimulates Th17 differentiation in vitro 
modulating phosphorylation of RelB 
and NF-κB1. Immunol Lett. 
May;165(1):10-9. doi: 10.1016/j.
imlet.2015.03.003. Epub 2015 Mar 17. 
PMID: 25794633.
[140] Boerhout, E., Vrieling, M., 
Benedictus, L., Daemen, I., Ravesloot, 
L., Rutten, V., Nuijten, P., Van Strijp, J., 
Koets, A. and Eisenberg, S., 2015. 
Immunization routes in cattle impact 
the levels and neutralizing capacity of 
antibodies induced against S. aureus 
immune evasion proteins. Veterinary 
research, 46(1), pp.1-9
[141] Fujimoto, K. and Uematsu, S., 
2020. Development of prime–boost-
type next-generation mucosal vaccines. 
International immunology, 32(9), 
pp.597-603.
[142] Pérez, M.M., Prenafeta, A., Valle, 
J., Penadés, J., Rota, C., Solano, C., 
Marco, J., Grilló, M.J., Lasa, I., Irache, 
J.M. and Maira-Litran, T., 2009. 
Protection from Staphylococcus aureus 
mastitis associated with poly-N-acetyl 
β-1, 6 glucosamine specific antibody 
production using biofilm-embedded 
bacteria. Vaccine, 27(17), pp.2379-2386. 
https://doi.org/10.1016/j.
vaccine.2009.02.005
[143] Vasileiou, N.G.C., Chatzopoulos, 
D.C., Cripps, P.J., Ioannidi, K.S., 
Gougoulis, D.A., Chouzouris, T.M., 
Lianou, D.T., Gonzalez-Valerio, T.C., 
Vallverdu, R.G., Argyros, S. and Cesio, 
M., 2019. Evaluation of efficacy of a 
biofilm-embedded bacteria-based 
vaccine against staphylococcal mastitis 
in sheep—A randomized, placebo-
controlled field study. Journal of dairy 
science, 102(10), pp.9328-9344. https://
doi.org/10.3168/jds.2019-16287
[144] N.G.C. Vasileiou, D.C. 
Chatzopoulos, P.J. Cripps, K.S. Ioannidi, 
D.A. Gougoulis, T.M. Chouzouris, D.T. 
Lianou, T. Calvo Gonzalez-Valerio, R. 
Guix Vallverdu, S. Argyros, M. Cesio, I. 
Font, V.S. Mavrogianni, E. Petinaki, 
G.C. Fthenakis. 2019. Evaluation of 
efficacy of a biofilm-embedded 
bacteria-based vaccine against 
staphylococcal mastitis in sheep—A 
randomized, placebo-controlled field 
study, Journal of Dairy Science, Volume 
102, Issue 10, Pages 9328-9344, ISSN 
0022-0302, https://doi.org/10.3168/
jds.2019-16287
